Sigma Healthcare Profit Jumps 22 per Cent as Annual Sales Top $10.8 Billion

Sigma Healthcare posted a 22.3 per cent rise in annual net profit to $732.3 million for the year ended June 30, lifted by pharmacy additions and GLP-1 prescription volumes.

Group revenue advanced 15.5 per cent to $10.8 billion, while normalised earnings before interest and taxes climbed 20.6 per cent to breach $1 billion.

The results reflect the first full operating cycle since Sigma combined operations with discount chain Chemist Warehouse. Chief Executive Officer Vikesh Ramsunder told investors the business now oversees nearly 1,000 pharmacies worldwide, supported by supply-chain integration across wholesale and retail divisions.

Chemist Warehouse Drives Domestic Momentum

Australia generated the bulk of earnings, lifting revenue 14.9 per cent to $10.4 billion and normalised operating profit by 18.3 per cent. Chemist Warehouse added 24 domestic sites to reach 561 stores, generating network sales growth of 15.9 per cent and same-store sales gains of 13.4 per cent.

Sales of GLP-1 weight-loss medications contributed heavily to turnover across the network. While the high-cost treatments carry lower percentage returns, Sigma maintained its Australian gross margin at 17.6 per cent by expanding front-of-store retail lines, introducing more than 470 private-label products during the financial year.

For retail pharmacy chains across the Asia-Pacific region, Sigma’s post-merger run shows how high-volume discount models can protect margins even as prescription product mixes shift toward expensive, low-margin therapies. It also demonstrates how domestic retail density provides cash flow stability after walking away from risky international takeovers, including Sigma’s abandoned $14 billion tilt at Britain’s Boots chain.

Synergies and Franchise Pipeline

Sigma captured $32.6 million in operational savings during the year as it works toward an annual cost-reduction target of $100 million by the 2029 financial year.

Wholesale franchise networks Amcal and Discount Drug Stores are also rebuilding footprint after years of store rationalisation. Management has assembled an opening pipeline of 82 stores, scheduled to return both banner groups to net store count growth during the 2027 financial year.